Home Use of an Artificial Beta Cell in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P<0.001). The mean glucose level was lower during the closed-loop phase than during the control phase (difference, -11 mg per deciliter; 95% CI, -17 to -6; P<0.001), as were the area under the curve for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0.5 to -0.1; P=0.002). Among children and adolescents, the proportion of time with the nighttime glucose level in the target range was higher during the closed-loop phase than during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per deciliter; 95% CI, -39 to -20; P<0.001). The area under the curve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P=0.03). Three severe hypoglycemic episodes occurred during the closed-loop phase when the closed-loop system was not in use. CONCLUSIONS: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and NCT01778348.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Medtronic 780G, 113,114 CamAPS FX, 115,116 and Diabeloop 117 received CE mark for use in European countries;”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 3×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 2×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
McKnight, J. A., Wild, S. H., Lamb, M. J. E., Cooper, M. N., Jones, T. W., Davis, E. A., Hofer, S., Fritsch, M., Schober, E., Svensson, J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12676 · Cited by 343 · cited 6×
“Knee-joint arthralgia 0 1 (3) 0 0 0 0 0 0”
InfluentialClosed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342 · cited 1×
“Gastroenteritis 0 2 (6) 3 (9) 0 0 0 0 0”
Self-citation
Cited by
Items 101–200 of 454
Current Status and Emerging Options for Automated Insulin Delivery Systems
Forlenza, G. P., & Lal, R. A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0514 · Cited by 67
Anderson, S. M., Buckingham, B. A., Breton, M. D., Robic, J. L., Barnett, C. L., Wakeman, C. A., Oliveri, M. C., Brown, S. A., Ly, T. T., Clinton, P. K., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0018 · Cited by 68
Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care
Wilmot, E. G., Choudhary, P., Leelarathna, L., & Baxter, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13842 · Cited by 72
“with day-and-night use of the closed-loop system than with the control system.(79) However, a more recent publication from the same group did not show improvements in GV measures with CoV.”
BackgroundMethodSelf-citationHermanns, N., Heinemann, L., Freckmann, G., Waldenmaier, D., & Ehrmann, D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819831695 · Cited by 66
Self-citationTime in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Benhalima, K., Beunen, K., Siegelaar, S. E., Painter, R., Murphy, H. R., Feig, D. S., Donovan, L. E., Polsky, S., Buschur, E., Levy, C. J., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00116-x · Cited by 61
Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users
Tanenbaum, M. L., Iturralde, E., Hanes, S. J., Suttiratana, S. C., Ambrosino, J. M., Ly, T. T., Maahs, D. M., Naranjo, D. M., Walders‐Abramson, N., WEINZIMER, S. A., et al. (2017) · Journal of Health Psychology · doi:10.1177/1359105317718615 · Cited by 68
“Email: kkhood@stanford.edu such systems have demonstrated success through keeping participants’ glucose levels within range 70–80 percent of the time (Ly and Buckingham, 2015; Russell et al., 2014, 2016; Thabit et al., 2015a, 2015b).”
BackgroundBondía, J., Romero‐Vivó, S., Ricarte, B., & Díez, J.-L. (2018) · IEEE Control Systems · doi:10.1109/mcs.2017.2766312 · Cited by 70
“Finally, another relevant MPC-based AP system is presented in [23], which was already tested in free living conditions without supervision over three months [54].”
BackgroundTsoukas, M. A., Majdpour, D., Yale, J.-F., Fathi, A. E., Garfield, N., Rutkowski, J., Rene, J., Legault, L., & Haidar, A. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00139-4 · Cited by 58
Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer, M. J., Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cobry, E. C., Messer, L. H., Cengiz, E., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0646 · Cited by 63
Self-citationA Review of Safety and Design Requirements of the Artificial Pancreas
Blauw, H., Keith-Hynes, P., Koops, R., & DeVries, J. H. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-016-1679-2 · Cited by 75
Herrero, P., Bondia, J., Adewuyi, O., Pesl, P., El-Sharkawy, M., Reddy, M., Toumazou, C., Oliver, N., & Georgiou, P. (2017) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.05.010 · Cited by 63
Cobry, E. C., Hamburger, E., & Jaser, S. S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0057 · Cited by 64
Mediatorless, Reversible Optical Nanosensor Enabled through Enzymatic Pocket Doping
Zubkovs, V., Schuergers, N., Lambert, B., Ahunbay, E., & Boghossian, A. A. (2017) · Small · doi:10.1002/smll.201701654 · Cited by 64
Infante, M., Baidal, D. A., Rickels, M. R., Fabbri, A., Skyler, J. S., Alejandro, R., & Ricordi, C. (2021) · Artificial Organs · doi:10.1111/aor.14023 · Cited by 66
Messori, M., Kropff, J., Del Favero, S., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., Lanzola, G., Farret, A., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0463 · Cited by 59
MOSQUERA-LOPEZ, C. M., Wilson, L. M., Youssef, J. E., Hilts, W. W., LEITSCHUH, J. A., Branigan, D. L., Gabo, V. B., Eom, J. H., Castle, J. R., & Jacobs, P. G. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00783-1 · Cited by 73
Thabit, H., & Hovorka, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115013 · Cited by 58
“[72] Larger and longer multicentre studies are being planned, and closed-loop insulin delivery systems may”
BackgroundSelf-citationLy, T. T., Weinzimer, S. A., Maahs, D. M., Sherr, J. L., Roy, A., Grosman, B., Cantwell, M., Kurtz, N., Carria, L., Messer, L., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12399 · Cited by 56
“Several closed-loop systems using different algorithmic approaches have demonstrated feasibility of automated insulin modulation in clinical studies and advances in both sensor performance and algorithms have incrementally demonstrated improved protection against hypoglycemia, reduced glucose variability and decreased…”
BackgroundIqbal, A., & Heller, S. R. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.004 · Cited by 64
“report three severe hypoglycaemic episodes during the closed-loop phase (114).”
BackgroundGlucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use
Taleb, N., Haidar, A., Messier, V., Gingras, V., Legault, L., & Rabasa‐Lhoret, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12789 · Cited by 59
“[7] Thabit H, Tauschmann M, Allen JM, et al.”
BackgroundFarina, M., Chua, C. Y. X., Ballerini, A., Thekkedath, U. R., Alexander, J. F., Rhudy, J. R., Torchio, G., Fraga, D. W., Pathak, R. R., Villanueva, M., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.047 · Cited by 62
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M. J., Jost, E., Carria, L., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1729 · Cited by 56
“70% plus time ,70 mg/dL ,4% 2 (9) 3 (14) 8 (36) NA 0.”
ResultSelf-citationNonadjunctive Use of Continuous Glucose Monitoring for Diabetes Treatment Decisions
Castle, J. R., & Jacobs, P. G. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816631569 · Cited by 56
“Importantly, in the Thabit et al study, 3 severe hypoglycemic events occurred, but only when the AP was not in use.(36) While the AP is not yet commercially available, numerous groups are moving in the direction of commercialization as summarized by Kowalski.”
BackgroundPrahalad, P., Zaharieva, D. P., Addala, A., New, C., Scheinker, D., Desai, M., Hood, K. K., & Maahs, D. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00360 · Cited by 51
Rossetti, P., Quirós, C., Moscardó, V., Comas, A., Giménez, M., Ampudia‐Blasco, F. J., Vargas, F. M. L., Montaser, E., Conget, I., Bondía, J., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0443 · Cited by 59
“However, the reduction of glycemic variability was mainly due to a diminution in nocturnal glycemic variability.(5,14) In addition, the PP period was not systematically addressed in these studies.”
Hajizadeh, I., Rashid, M. M., Turksoy, K., Samadi, S., Feng, J., Sevil, M., Hobbs, N., Lazaro, C., Maloney, Z., Littlejohn, E., et al. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818789951 · Cited by 58
Jendle, J., Pöhlmann, J., de Portu, S., Smith-Palmer, J., & Roze, S. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0328 · Cited by 52
Ly, T. T., Keenan, D. B., Roy, A., Han, J., Grosman, B., Cantwell, M., Kurtz, N., von Eyben, R., Clinton, P., Wilson, D. M., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0431 · Cited by 51
“Most recently, the group reported results from their 3-month crossover trial, and for their adolescent cohort, time in range was improved from 34% to 60% with closed-loop control.(24)”
Enhanced Model Predictive Control (eMPC) Strategy for Automated Glucose Control
Lee, J. B., Dassau, E., Gondhalekar, R., Seborg, D. E., Pinsker, J. E., & Doyle, F. J. (2016) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.6b02718 · Cited by 54
Evaluation of a Predictive Low-Glucose Management System In-Clinic
Buckingham, B. A., Bailey, T. S., Christiansen, M., Garg, S., Weinzimer, S., Bode, B., Anderson, S. M., Brazg, R., Ly, T. T., & Kaufman, F. R. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0319 · Cited by 52
Wang, T., Wang, D., Zhang, L., Yang, P. C., Wang, J., Liu, Q., Yan, F., & Lin, F. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1195-y · Cited by 53
Overnight glucose control in people with type 1 diabetes
Boiroux, D., Duun‐Henriksen, A. K., Schmidt, S., Nørgaard, K., Madsbad, S., Poulsen, N. K., Madsen, H., & Jørgensen, J. B. (2017) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2017.08.005 · Cited by 56
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 66
Fan, W., Deng, C., Xu, R., Liu, Z., Leslie, R. D., Zhou, Z., & Li, X. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0130 · Cited by 58
Automated insulin delivery systems: from early research to routine care of type 1 diabetes
Renard, É. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01929-5 · Cited by 58
“An extension of this trial investigated 24/7 closed-loop use up to 6 months and reported the sustained improvement of median time in target glucose range which was 77% against 66% at baseline [41].”
BackgroundHybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions
Grosman, B., Ilany, J., Roy, A., Kurtz, N., Wu, D., Parikh, N., Voskanyan, G., Konvalina, N., Mylonas, C., Gottlieb, R., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816631568 · Cited by 48
“studies.(8-14) The CGM to insulin feedback titration algorithm generally implements either modifications of the proportional-integral-derivative (PID)(15) controller, the model predictive controller (MPC)(16) or fuzzy-logic(17) control.”
MethodChristiansen, S. C., Fougner, A. L., Stavdahl, Ø., Kölle, K., Ellingsen, R., & Carlsen, S. M. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0263-6 · Cited by 55
“Time in hyperglycemia during the daytime in the few studies which explicitly report daytime data appears to be higher than the time in hyperglycemia reported for 24-h data (Table 2) [30, 31].”
BackgroundInfluentialFrom Wary Wearers to d-Embracers: Personas of Readiness to Use Diabetes Devices
Tanenbaum, M. L., Adams, R. N., Iturralde, E., Hanes, S. J., Barley, R. C., Naranjo, D. M., & Hood, K. K. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818793756 · Cited by 49
Therapy-driven Deep Glucose Forecasting
Aiello, E. M., Lisanti, G., Magni, L., Musci, M., & Toffanin, C. (2019) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2019.103255 · Cited by 54
A critical review and analysis of ethical issues associated with the artificial pancreas
Quintal, A., Messier, V., RABASA-LHORET, R. P. R., & Racine, É. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.04.003 · Cited by 51
Huyett, L. M., Dassau, E., Zisser, H., & Doyle, F. J. (2018) · IEEE Control Systems · doi:10.1109/mcs.2017.2766322 · Cited by 51
“[25] H.”
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Michou, P., Gkiourtzis, Ν., Christoforidis, A., Kotanidou, E. P., & Galli-Tsinopoulou, A. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110678 · Cited by 51
Future of Automated Insulin Delivery Systems
Castle, J. R., DeVries, J. H., & Kovatchev, B. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0012 · Cited by 45
“%) compared with SAP.37 Adults used the AP system day and night for 12 weeks, whereas children and adolescents used the system overnight for 12 weeks.”
MethodAleppo, G., & Webb, K. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0097 · Cited by 44
Haidar, A., Lovblom, L. E., Cardinez, N., Gouchie‐Provencher, N., Orszag, A., Tsoukas, M. A., Falappa, C. M., Jafar, A., Ghanbari, M., Eldelekli, D., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01805-3 · Cited by 48
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
Self-citationAlbers, D. J., Levine, M. E., Stuart, A., Mamykina, L., Gluckman, B., & Hripcsak, G. (2018) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocy106 · Cited by 43
Asarani, N. A. M., Reynolds, A. N., Elbalshy, M. M., Burnside, M. J., de Bock, M. I., Lewis, D. M., & Wheeler, B. J. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01623-4 · Cited by 46
Haidar, A., Yale, J., Lovblom, L. E., Cardinez, N., Orszag, A., Falappa, C. M., Gouchie‐Provencher, N., Tsoukas, M. A., El Fathi, A., Rene, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14335 · Cited by 42
van Veldhuisen, C. L., Latenstein, A. E. J., Blauw, H., Vlaskamp, L. B., Klaassen, M., Lips, D. J., Bonsing, B. A., van der Harst, E., Stommel, M. W. J., Bruno, M. J., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.3702 · Cited by 51
Nimri, R., Bratina, N., Kordonouri, O., Avbelj Stefanija, M., Fath, M., Biester, T., Muller, I., Atlas, E., Miller, S., Fogel, A., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12852 · Cited by 42
“In fact, the Cambridge group have already published successful trials in adults and adolescents in unsupervised home studies.(29,30) Integration of the system into the daily life of patients was simple.”
BackgroundMethodThe role of glucagon in the artificial pancreas
Haidar, A., Smaoui, M. R., Legault, L., & RABASA-LHORET, R. P. R. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30006-7 · Cited by 46
A Review of Safety and Hazards Associated With the Artificial Pancreas
Ramkissoon, C. M., Aufderheide, B., Bequette, B. W., & Vehí, J. (2017) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2749038 · Cited by 47
“Another outpatient study [252] reported that more than 50% of the interruptions were attributable to lack of pump connectivity.”
BackgroundGlucose-responsive insulin delivery for type 1 diabetes: The artificial pancreas story
Bally, L., Thabit, H., & Hovorka, R. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.022 · Cited by 43
“The longest randomised study by Thabit et al contrasted day-and-night hybrid closed-loop use with sensor-augmented pump therapy over three months and showed improvements in time in target glucose range, HbA1c and hypoglycaemia (Thabit et al., 2015).”
BackgroundSelf-citationAutomated blood glucose control in type 1 diabetes: A review of progress and challenges
Bertachi, A. H., Ramkissoon, C. M., Bondía, J., & Vehí, J. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.10.011 · Cited by 45
Kropff, J., DeJong, J., del Favero, S., Place, J., Messori, M., Coestier, B., Farret, A., Boscari, F., Galasso, S., Avogaro, A., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13268 · Cited by 40
Pinsker, J. E., Laguna Sanz, A. J., Lee, J. B., Church, M. M., Andre, C., Lindsey, L. E., Doyle, F. J., & Dassau, E. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0031 · Cited by 39
Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index
Leelarathna, L., Thabit, H., Wilinska, M. E., Bally, L., Mader, J. K., Pieber, T. R., Benesch, C., Arnolds, S., Johnson, T. K., Heinemann, L., et al. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819838525 · Cited by 41
“(based on reference 16) The total and individual components of COGI were calculated in adults with type 1 diabetes treated with multiple daily injection therapy (MDI) or continuous subcutaneous insulin infusion (CSII) from 4 previously published RCTs.(3,4,11,12) Study design and methods of these studies have been publ…”
MethodSelf-citationMultivariate learning framework for long‐term adaptation in the artificial pancreas
Shi, D., Dassau, E., & Doyle, F. J. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10119 · Cited by 39
Pease, A., Zomer, E., Liew, D., Earnest, A., Soldatos, G., Ademi, Z., & Zoungas, S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0064 · Cited by 39
Embedded Control in Wearable Medical Devices: Application to the Artificial Pancreas
Zavitsanou, S., Chakrabarty, A., Dassau, E., & Doyle, F. J. (2016) · Processes · doi:10.3390/pr4040035 · Cited by 44
“A hand-held computer [29] was used to run the control algorithm in [30,31].”
MethodGlucose-insulin model identified in free-living conditions for hypoglycaemia prevention
Toffanin, C., Favero, S. D., Aiello, E. M., Messori, M., Cobelli, C., & Magni, L. (2018) · Journal of Process Control · doi:10.1016/j.jprocont.2018.02.003 · Cited by 39
Toffanin, C., Aiello, E. M., Favero, S. D., Cobelli, C., & Magni, L. (2019) · Journal of Process Control · doi:10.1016/j.jprocont.2019.03.007 · Cited by 43
Burckhardt, M., Abraham, M. B., Dart, J., Smith, G. J., Paramalingam, N., O’Dea, J. M., de Bock, M. I., Davis, E. A., & Jones, T. W. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0593 · Cited by 43
Stahl‐Pehe, A., Mashhadi, N. S., Wirth, M., Schlesinger, S., Kuß, O., Holl, R. W., Bächle, C., Warz, K.-D., Bürger-Büsing, J., Spörkel, O., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103190 · Cited by 42
Bode, B. W., Carlson, A. L., Liu, R., Hardy, T. A., Bergenstal, R. M., Boyd, J., Morrett, S., & Ignaut, D. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0184 · Cited by 38
Scully, K. J., Palani, G., Zheng, H., Moheet, A., & Putman, M. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0354 · Cited by 37
Haidar, A., Legault, L., Raffray, M., Gouchie‐Provencher, N., Jafar, A., Devaux, M., Ghanbari, M., & RABASA-LHORET, R. P. R. (2023) · Diabetes Care · doi:10.2337/dc22-2297 · Cited by 46
“Current automated insulin delivery systems improve glycemic control compared with pump therapy and sensor-augmented pump therapy (2,3).”
BackgroundMOSQUERA-LOPEZ, C. M., & Jacobs, P. G. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211042621 · Cited by 44
Closed-loop for type 1 diabetes – an introduction and appraisal for the generalist
Bally, L., Thabit, H., & Hovorka, R. (2017) · BMC Medicine · doi:10.1186/s12916-017-0794-8 · Cited by 38
“Evidence is being collected in large randomised clinical trials to justify the use of the technology in a wide range population to funders and healthcare professionals [16, 19, 21, 27], as well as elucidating its glycaemia-related and psychosocial impacts.”
BackgroundSelf-citationNew directions for diabetes prevention and management in behavioral medicine
Stetson, B. A., Minges, K. E., & Richardson, C. R. (2016) · Journal of Behavioral Medicine · doi:10.1007/s10865-016-9802-2 · Cited by 42
“The use of such technologies must be considered along with advancements in medical devices, such as continuous glucose monitoring and use of artificial beta cell or closedloop insulin-delivery systems (Thabit et al., 2015).”
MethodMultivariable Adaptive Artificial Pancreas System in Type 1 Diabetes
Çınar, A. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0920-1 · Cited by 37
Bassi, M., Franzone, D., Dufour, F., Strati, M. F., Scalas, M., Tantari, G., Aloi, C., Salina, A., d’Annunzio, G., Maghnie, M., et al. (2023) · Life · doi:10.3390/life13030783 · Cited by 46
Jacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A. X., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00358-x · Cited by 40
Finding the right route for insulin delivery – an overview of implantable pump therapy
Bally, L., Thabit, H., & Hovorka, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1267138 · Cited by 34
“This may also enhance closed-loop performance, which is currently hampered by delayed subcutaneous insulin kinetics [58,59].”
Self-citationExecutive Summary of IPITA-TTS Opinion Leaders Report on the Future of β-Cell Replacement
Markmann, J. F., Bartlett, S. T., Johnson, P., Korsgren, O., Hering, B. J., Scharp, D. W., Kay, T. W. H., Bromberg, J. S., Odorico, J. S., Weir, G. C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001054 · Cited by 35
Hanazaki, K., Munekage, M., Kitagawa, H., Yatabe, T., Munekage, E., Shiga, M., Maeda, H., & Namikawa, T. (2016) · Journal of Artificial Organs · doi:10.1007/s10047-016-0904-y · Cited by 35
“proposed that intensive insulin therapy (IIT), targeting a blood glucose level of 80–110 mg/dL, could significantly reduce morbidity and mortality in critically ill surgical intensive care unit (ICU) patients compared with conventional glycemic control methods [7].”
BackgroundAutomated Insulin Delivery in Adults
Boughton, C. K., & Hovorka, R. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.007 · Cited by 34
Self-citationAsgharzadeh, A., Patel, M., Connock, M. J., Damery, S. L., Ghosh, I., Jordan, M., Freeman, K., Brown, A., Court, R. A., Baldwin, S., et al. (2024) · Health Technology Assessment · doi:10.3310/jypl3536 · Cited by 37
Benhamou, P., Huneker, E., Franc, S., Doron, M., & Charpentier, G. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1123-1 · Cited by 32
The automated pancreas: A review of technologies and clinical practice
Biester, T., Tauschmann, M., Chobot, A. P., Kordonouri, O., Danne, T., Kapellen, T. M., & Dovč, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14576 · Cited by 34
Self-citationPaldus, B., Morrison, D., Lee, M., Zaharieva, D. P., Riddell, M. C., & O'Neal, D. N. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088327 · Cited by 37
de Bock, M. I., Dart, J., Roy, A., Davey, R. J., Soon, W. H. K., Berthold, C. L., Retterath, A. J., Grosman, B., Kurtz, N., Davis, E. A., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816668876 · Cited by 31
“We conclude that (1) algorithm refinement for this HCL system continues to be required in preparation for long-term home trials, (2) HCL systems that rely on accurate carbohydrate counting and appropriate carbohydrate ratios are vulnerable to daytime hypoglycemia and therefore clinical review and patient education wil…”
BackgroundHaidar, A., Legault, L., Raffray, M., Gouchie‐Provencher, N., Jacobs, P. G., Fathi, A. E., Rutkowski, J., Messier, V., & RABASA-LHORET, R. P. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0365 · Cited by 34
Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes
Dadlani, V., Pinsker, J. E., Dassau, E., & Kudva, Y. C. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1051-z · Cited by 32
Lee, M. H., Vogrin, S., Paldus, B., Jones, H. M., Obeyesekere, V. R., Sims, C. M., WYATT, S. A., Ward, G. M., McAuley, S. A., MacIsaac, R. J., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0120 · Cited by 30
Morrison, D., Zaharieva, D. P., Lee, M. H., Paldus, B., Vogrin, S., Grosman, B., Roy, A., Kurtz, N., & O'Neal, D. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0221 · Cited by 32
Kang, S. L., Hwang, Y. N., Kwon, J. Y., & Kim, S. M. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00962-2 · Cited by 32
“[61] 2015 33 Florence with freestyle navigator MPC SAP 24 h 12 weeks”
BackgroundSpaic, T., Driscoll, M., Raghinaru, D., Buckingham, B. A., Wilson, D. M., Clinton, P., Chase, H. P., Maahs, D. M., Forlenza, G. P., Jost, E., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1794 · Cited by 29
Self-citationPenaforte-Saboia, J. G., Couri, C. E. B., Albuquerque, N. V., Silva, V. L. L., Olegário, N. B. D. C., Fernandes, V. O., & Montenegro, R. M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s294742 · Cited by 33
“cemic adjustment, adequate nutrition, and adherence to physical activity have a limited patient compliance.(21,22)”
BackgroundMcAuley, S. A., de Bock, M. I., Sundararajan, V., Lee, M. H., Paldus, B., Ambler, G. R., Bach, L. A., Burt, M. G., Cameron, F. J., Clarke, P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020274 · Cited by 29
Insulin-and-Glucagon Artificial Pancreas Versus Insulin-Alone Artificial Pancreas: A Short Review
Haidar, A. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0097 · Cited by 30
“However, clinically significant hypoglycemia and hyperglycemia still exist with the artificial pancreas (5,6).”
BackgroundRidder, F. D., den Brinker, M., & Block, C. E. M. D. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819871903 · Cited by 32
Automated Insulin Delivery for Pregnant Women With Type 1 Diabetes: Where Do We Stand?
Benhalima, K., JENDLE, J. H., Beunen, K., & Ringholm, L. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223934 · Cited by 28
“35,36 Both rapid and ultra-rapid insulin analogues can be used.”
Forlenza, G. P., Raghinaru, D., Cameron, F. M., Bequette, B. W., Chase, H. P., Wadwa, R. P., Maahs, D. M., Jost, E., Ly, T. T., Wilson, D. M., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12603 · Cited by 28
Self-citationLeelarathna, L., Beck, R. W., Bergenstal, R. M., Thabit, H., & Hovorka, R. (2019) · Diabetes Care · doi:10.2337/dc18-2479 · Cited by 28
“dren and Adolescents With Type 1 Diabetes in the Home Setting) (n = 25, Navigator 2) (3).”
BackgroundSelf-citationJafar, A., Fathi, A. E., & Haidar, A. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.105936 · Cited by 30
Rankin, D., Kimbell, B., Allen, J. M., Besser, R. E. J., Boughton, C. K., Campbell, F., Elleri, D., Fuchs, J., Ghatak, A., Randell, T. L., et al. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821994201 · Cited by 30
Self-citation
Metadata
- Authors
- Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., Mader, J. K., Holzer, M., Kojzar, H., Exall, J., Yong, J., Pichierri, J., Barnard, K. D., Kollman, C., Cheng, P., Hindmarsh, P. C., Campbell, F. M., Arnolds, S., Pieber, T. R., Evans, M. L., Dunger, D. B., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Profil Institute for Metabolic Research (DE)
- Medical University of Graz (AT)
- Leeds Teaching Hospitals NHS Trust (GB)
- University College Hospital (GB)
- Bournemouth University (GB)
- Jaeb Center for Health Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2129-2140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4697362
- OpenAlex
- W2332531077
- Cited by
- 450
- References
- 29
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 29 · 2022: 31 · 2021: 43 · 2020: 34 · 2019: 49 · 2018: 71 · 2017: 71 · 2016: 68 · 2015: 10
- FWCI
- 63.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Wellcome Trust (100574, 100574/Z/12/Z)
- National Institute for Health and Care Research (NF-SI-0508-10274, NF-SI-0513-10012, CAMBRC-2012-1)
- Swansea University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, artificial beta cell, sensor-augmented pump therapy, glycemic variability, HbA1c, children and adolescents, adults, continuous glucose monitoring, insulin pump therapy, free-living conditions, hypoglycemia risk reduction, glycemic control
- MeSH terms
- Adolescent, Adult, Algorithms, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Infusion Pumps, Implantable, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.